181 related articles for article (PubMed ID: 30198510)
21. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
[TBL] [Abstract][Full Text] [Related]
22. Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis.
Peterson ND; Rosen BC; Dillon NA; Baughn AD
Antimicrob Agents Chemother; 2015 Dec; 59(12):7320-6. PubMed ID: 26369957
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
24. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH
Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Liu W; Chen J; Shen Y; Jin J; Wu J; Sun F; Wu Y; Xie L; Zhang Y; Zhang W
Clin Microbiol Infect; 2018 Sep; 24(9):1016.e1-1016.e5. PubMed ID: 29288021
[TBL] [Abstract][Full Text] [Related]
26. [A study of the bacteriophage-based assay for the detection of pyrazinamide resistance in Mycobacterium tuberculosis].
Ao JP; Chen JW; Hu ZY; Li JN; Wang J; Wang Q; Cui ZL; Zhang WH; Wong XH
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):625-8. PubMed ID: 17129472
[TBL] [Abstract][Full Text] [Related]
27. Revisiting problems and solutions to decrease Mycobacterium tuberculosis pyrazinamide false resistance when using the Bactec MGIT 960 system.
Mustazzolu A; Piersimoni C; Iacobino A; Giannoni F; Chirullo B; Fattorini L
Ann Ist Super Sanita; 2019; 55(1):51-54. PubMed ID: 30968836
[TBL] [Abstract][Full Text] [Related]
28. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.
Dillon NA; Peterson ND; Rosen BC; Baughn AD
Antimicrob Agents Chemother; 2014 Dec; 58(12):7258-63. PubMed ID: 25246400
[TBL] [Abstract][Full Text] [Related]
29. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
30. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?
Heifets LB; Flory MA; Lindholm-Levy PJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1252-4. PubMed ID: 2508544
[TBL] [Abstract][Full Text] [Related]
31. Immunological detection of pyrazine-2-carboxylic acid for the detection of pyrazinamide resistance in Mycobacterium tuberculosis.
Florentini EA; Angulo N; Gilman RH; Alcántara R; Roncal E; Antiparra R; Toscano E; Vallejos K; Kirwan D; Zimic M; Sheen P
PLoS One; 2020; 15(11):e0241600. PubMed ID: 33151985
[TBL] [Abstract][Full Text] [Related]
32. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations.
Gu Y; Yu X; Jiang G; Wang X; Ma Y; Li Y; Huang H
Diagn Microbiol Infect Dis; 2016 Mar; 84(3):207-11. PubMed ID: 26775806
[TBL] [Abstract][Full Text] [Related]
33. Detection of
Willby MJ; Wijkander M; Havumaki J; Johnson K; Werngren J; Hoffner S; Denkinger CM; Posey JE
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084743
[TBL] [Abstract][Full Text] [Related]
34. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
35. [Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey].
Senol G; Coşkun M; Gündüz AT; Biçmen C; Gayaf M; Ozsöz A
Mikrobiyol Bul; 2008 Oct; 42(4):591-7. PubMed ID: 19149080
[TBL] [Abstract][Full Text] [Related]
36. Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate.
Hu Y; Wu X; Luo J; Fu Y; Zhao L; Ma Y; Li Y; Liang Q; Shang Y; Huang H
Clin Microbiol Infect; 2017 Nov; 23(11):835-838. PubMed ID: 28411185
[TBL] [Abstract][Full Text] [Related]
37. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
38. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis using the fast resazurin microtiter assay plate.
Pina RZ; Caleffi-Ferracioli KR; Campanerut-Sá PA; Ghiraldi-Lopez LD; Pavan FR; Siqueira VL; Scodro RB; Cardoso RF
Int J Tuberc Lung Dis; 2016 Nov; 20(11):1535-1538. PubMed ID: 27776597
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates.
Huy NQ; Lucie C; Hoa TTT; Hung NV; Lan NTN; Son NT; Nhung NV; Anh DD; Anne-Laure B; Van Anh NT
Emerg Microbes Infect; 2017 Oct; 6(10):e86. PubMed ID: 29018250
[TBL] [Abstract][Full Text] [Related]
40. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
